Stay updated on IL-15 Combo with Nivolumab & Ipilimumab in Refractory Cancers Clinical Trial
Sign up to get notified when there's something new on the IL-15 Combo with Nivolumab & Ipilimumab in Refractory Cancers Clinical Trial page.

Latest updates to the IL-15 Combo with Nivolumab & Ipilimumab in Refractory Cancers Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe site footer now identifies the ClinicalTrials.gov release as v3.8.0 instead of v3.7.2.SummaryDifference0.0%

- Check22 days agoChange DetectedA notice was added announcing NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology.SummaryDifference0.2%

- Check29 days agoChange DetectedThe website footer revision changed from v3.7.1 to v3.7.2.SummaryDifference0.0%

- Check36 days agoChange DetectedThe site footer revision label changed from v3.7.0 to v3.7.1.SummaryDifference0.0%

- Check50 days agoChange DetectedThe version history shows repeated updates to the study status and eligibility sections, documenting how the trial record has evolved over time. These edits reflect ongoing management and refinement of the trial's public information.SummaryDifference0.0%

- Check57 days agoChange DetectedRevision: v3.7.0 was added to the Record History as the latest update to the study record. Revision: v3.6.6 was removed from the history.SummaryDifference0.0%

Stay in the know with updates to IL-15 Combo with Nivolumab & Ipilimumab in Refractory Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IL-15 Combo with Nivolumab & Ipilimumab in Refractory Cancers Clinical Trial page.